Informations sur le produit
Nom :
HMN-214
Synonymes :
- (E)-4-[2-[2-[N-Acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide
- Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-
- Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-, (E)-
- Hmn-214
- Ivx 214
- N-[(4-Methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]acetamide
Description :
HMN-214 is a novel oral prodrug that is being developed as a single agent therapy for the treatment of cancer. HMN-214 is a prodrug of the natural product dihydromyricetin, which inhibits mitochondrial complex I and II. HMN-214 has shown potent antitumor activity in tumor xenografts and demonstrated safety profile in vivo. The drug also induces cancer cell death via a mechanism that involves inhibition of kinase domain phosphorylation, leading to apoptosis induction. HMN-214 has been tested in vitro and in vivo for pharmacokinetics and gene expression profiling with promising results.
Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :
Propriétés chimiques
Masse moléculaire :
424.47 g/mol
Formule :
C22H20N2O5S
Degré de pureté :
Min. 95%
MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :
